| Literature DB >> 31602424 |
Maria Grandoch1, Ulrich Flögel2, Sam Virtue3, Julia K Maier1, Tomas Jelenik4,5, Christina Kohlmorgen1, Kathrin Feldmann1, Yanina Ostendorf1, Tamara R Castañeda5,6, Zhou Zhou5,6, Yu Yamaguchi7, Emmani B M Nascimento8, Vivekananda G Sunkari9, Christine Goy10, Martina Kinzig11, Fritz Sörgel11, Paul L Bollyky9, Patrick Schrauwen8, Hadi Al-Hasani5,6, Michael Roden4,5,12, Susanne Keipert5,13,14, Antonio Vidal-Puig3,15, Martin Jastroch5,13,14, Judith Haendeler10,16, Jens W Fischer1.
Abstract
Therapeutic increase of brown adipose tissue (BAT) thermogenesis is of great interest as BAT activation counteracts obesity and insulin resistance. Hyaluronan (HA) is a glycosaminoglycan, found in the extracellular matrix, which is synthesized by HA synthases (Has1/Has2/Has3) from sugar precursors and accumulates in diabetic conditions. Its synthesis can be inhibited by the small molecule 4-methylumbelliferone (4-MU). Here, we show that the inhibition of HA-synthesis by 4-MU or genetic deletion of Has2/Has3 improves BAT`s thermogenic capacity, reduces body weight gain, and improves glucose homeostasis independently from adrenergic stimulation in mice on diabetogenic diet, as shown by a magnetic resonance T2 mapping approach. Inhibition of HA synthesis increases glycolysis, BAT respiration and uncoupling protein 1 expression. In addition, we show that 4-MU increases BAT capacity without inducing chronic stimulation and propose that 4-MU, a clinically approved prescription-free drug, could be repurposed to treat obesity and diabetes.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31602424 PMCID: PMC6786893 DOI: 10.1038/s42255-019-0055-6
Source DB: PubMed Journal: Nat Metab ISSN: 2522-5812